Maverick Capital Ltd. Purchases New Shares in Integra LifeSciences Holdings Corporation $IART

Maverick Capital Ltd. acquired a new stake in Integra LifeSciences Holdings Corporation (NASDAQ:IART) during the first quarter, HoldingsChannel reports. The fund acquired 72,108 shares of the life sciences company’s stock, valued at approximately $679,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of IART. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Integra LifeSciences by 5.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,441 shares of the life sciences company’s stock worth $889,000 after buying an additional 1,975 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in Integra LifeSciences in the 1st quarter valued at $277,000. Goldman Sachs Group Inc. lifted its position in shares of Integra LifeSciences by 2.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,660,511 shares of the life sciences company’s stock valued at $36,515,000 after acquiring an additional 35,790 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Integra LifeSciences by 23.0% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 244,335 shares of the life sciences company’s stock valued at $5,373,000 after acquiring an additional 45,693 shares during the period. Finally, Marshall Wace LLP acquired a new stake in shares of Integra LifeSciences during the 2nd quarter worth $491,000. Institutional investors and hedge funds own 84.78% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently commented on IART shares. Wall Street Zen cut Integra LifeSciences from a “strong-buy” rating to a “buy” rating in a research report on Saturday, July 18th. Wells Fargo & Company upped their price objective on shares of Integra LifeSciences from $12.00 to $15.00 and gave the stock an “equal weight” rating in a research report on Wednesday, May 6th. Truist Financial increased their price objective on shares of Integra LifeSciences from $14.00 to $19.00 and gave the stock a “hold” rating in a research note on Thursday, July 16th. Argus raised shares of Integra LifeSciences from a “hold” rating to a “buy” rating and set a $25.00 target price on the stock in a report on Thursday, June 18th. Finally, Weiss Ratings upgraded shares of Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, May 13th. One analyst has rated the stock with a Buy rating, five have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Reduce” and an average target price of $18.43.

Integra LifeSciences Stock Up 1.2%

IART stock opened at $19.76 on Wednesday. The firm has a 50-day moving average price of $17.61 and a 200-day moving average price of $13.41. Integra LifeSciences Holdings Corporation has a 12 month low of $8.70 and a 12 month high of $20.49. The company has a current ratio of 3.38, a quick ratio of 1.95 and a debt-to-equity ratio of 1.75. The stock has a market capitalization of $1.54 billion, a P/E ratio of -3.06, a price-to-earnings-growth ratio of 1.35 and a beta of 1.22.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings results on Tuesday, May 5th. The life sciences company reported $0.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.41 by $0.13. The company had revenue of $391.92 million for the quarter, compared to analyst estimates of $381.81 million. Integra LifeSciences had a negative net margin of 30.15% and a positive return on equity of 17.42%. The firm’s revenue was up 2.4% on a year-over-year basis. During the same period in the previous year, the firm posted $0.41 EPS. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. As a group, equities research analysts anticipate that Integra LifeSciences Holdings Corporation will post 2.45 EPS for the current fiscal year.

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.